BCYC News and Press, Bicycle Therapeutics plc From 10/12/21

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that it has commenced an underwritten public offering of $125,000,0...

- BT5528 Phase I anti-tumor activity observed in late line patients, with 2 partial responses out of 2 urothelial cancer patients dosed and an 80% disease control rate in 5 EphA2-positive ovarian cancer patients, including 1 partial response - A recommended BT5528 Phase II dos...

Gainers: Camber Energy (NYSE:CEI) +97%. Merus (NASDAQ:MRUS) +32%. New Fortress Energy (NASDAQ:NFE) +25%. Paltalk (NASDAQ:PALT) +25%. Grom Social Enterprises (NASDAQ:GROM) +20%. DatChat (NASDAQ:DATS) +20%. Jupiter Wellness (NASDAQ:JUPW) +18%. NextPlay Technologies (NASDAQ:NXTP) +19%. Independe...

- Company to host conference call on Thursday, October 7, 2021 at 3:00 p.m. ET Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technolog...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will participate in the following investor conferenc...

Bicycles are a new therapeutic modality wholly-owned by Bicycle Therapeutics. The Company’s platform has versatile combinatorial potential. The Company has collaboration agreements worth over a billion dollars. For further details see: Bicycle Therapeutics: Scaffo...

Bicycle Therapeutics (NASDAQ:BCYC): Q2 GAAP EPS of -$0.74 misses by $0.02. Revenue of $1.79M (+14.0% Y/Y) misses by $0.52M. Cash was $198.7 million as of June 30, 2021, which excludes $71.9 million received in July from both the Ionis collaboration upfront and net proceeds from the at-the-mar...

- Entered exclusive license and collaboration agreement with Ionis Pharmaceuticals to develop targeted oligonucleotide therapeutics - Cash was $198.7 million as of June 30, 20 21, which excludes $71.9 million received in July from both the Ionis collaboration upfront and n...

Ionis Pharmaceuticals (IONS) has entered into an exclusive licensing agreement with Bicycle Therapeutics (BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense ((LICA)) medicines.The agreement provides Ionis exclusive access to Bicycle's proprietary macroc...

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology - Exclusive rights to innovative peptide technology positions Ionis to further strengthen targeting capabilities of its LICA therapies PR Newswire CARLSB...